Clinical Trials Directory

Trials / Conditions / Endometrial Undifferentiated Carcinoma

Endometrial Undifferentiated Carcinoma

14 registered clinical trials studyying Endometrial Undifferentiated Carcinoma — 2 currently recruiting.

StatusTrialSponsorPhase
WithdrawnPET/MRI in Endometrial Cancer
NCT05390021
Massachusetts General HospitalN/A
RecruitingTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Se
NCT05256225
National Cancer Institute (NCI)Phase 3
RecruitingTesting Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial
NCT05112601
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTesting the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel a
NCT03914612
National Cancer Institute (NCI)Phase 3
Active Not RecruitingTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and C
NCT03660826
National Cancer Institute (NCI)Phase 2
CompletedCopanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02728258
NRG OncologyPhase 2
UnknownPaclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or
NCT02065687
Gynecologic Oncology GroupPhase 2 / Phase 3
CompletedNab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance
NCT02020707
Mayo ClinicPhase 1
CompletedTrametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01935973
National Cancer Institute (NCI)Phase 1
CompletedDalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01642082
Gynecologic Oncology GroupPhase 2
CompletedNintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887
Gynecologic Oncology GroupPhase 2
CompletedDasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT01440998
National Cancer Institute (NCI)Phase 1
CompletedBrivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00888173
Gynecologic Oncology GroupPhase 2
CompletedIntraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV En
NCT00575952
Gynecologic Oncology GroupPhase 1